Abstract
Allergen-specific immunotherapy is the only immunomodulatory treatment that may alter the natural course of allergic disease. However, cytokine responses accompanying sublingual immunotherapy (SLIT) responder phenotypes have not been fully understood. Herein, we examined the level of crucial plasma cytokines during SLIT and evaluated whether their changes correlated to symptom scores. We observed that the levels of interleukin (IL)-17 and complement components C3a and C5a as well as IL-4 at year 3 of SLIT were significantly decreased than those at baseline. In contrast, there was no significant difference in the levels of IL-5, IL-13, and interferon (IFN)-γ. Notably, a significant positive correlation was found between the levels of IL-17 and the symptom scores at year 3. These results suggest that IL-17 could be considered a potential biomarker for the therapeutic effect of SLIT in allergic rhinitis caused by house dust mite.
Similar content being viewed by others
REFERENCES
Compalati, E., G. Passalacqua, M. Bonini, and G.W. Canonica. 2009. The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis. Allergy 64: 1570–1579.
Radulovic, S., D. Wilson, M. Calderon, and S. Durham. 2011. Systematic reviews of sublingual immunotherapy (SLIT). Allergy 66: 740–752.
Walker, S.M., S.R. Durham, S.J. Till, G. Roberts, C.J. Corrigan, S.C. Leech, et al. 2011. Immunotherapy for allergic rhinitis. Clinical and Experimental Allergy 41: 1177–1200.
Wilson, D.R., M.T. Lima, and S.R. Durham. 2005. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 60: 4–12.
Penagos, M., E. Compalati, F. Tarantini, R. Baena-Cagnani, J. Huerta, G. Passalacqua, et al. 2006. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Annals of Allergy, Asthma & Immunology 97: 141–148.
Mortemousque, B., F. Bertel, J. De Casamayor, P. Verin, and J. Colin. 2003. House-dust mite sublingual-swallow immunotherapy in perennial conjunctivitis: a double-blind, placebo-controlled study. Clinical and Experimental Allergy 33: 464–469.
Passalacqua, G., M. Pasquali, R. Ariano, C. Lombardi, A. Giardini, I. Baiardini, et al. 2006. Randomized double-blind controlled study with sublingual carbamylated allergoid immunotherapy in mild rhinitis due to mites. Allergy 61: 849–854.
de Blay, F., C. Barnig, G. Kanny, A. Purohit, F. Leynadier, J.M. Tunon de Lara, et al. 2007. Sublingual-swallow immunotherapy with standardized 3-grass pollen extract: a double-blind, placebo-controlled study. Annals of Allergy, Asthma & Immunology 99: 453–461.
Bohle, B., T. Kinaciyan, M. Gerstmayr, A. Radakovics, B. Jahn-Schmid, and C. Ebner. 2007. Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. Journal of Allergy and Clinical Immunology 120: 707–713.
Guez, S., C. Vatrinet, R. Fadel, and C. Andre. 2000. House-dust-mite sublingual-swallow immunotherapy (SLIT) in perennial rhinitis: a double-blind, placebo-controlled study. Allergy 55: 369–375.
Canonica, G.W., C.E. Baena-Cagnani, J. Bousquet, P.J. Bousquet, R.F. Lockey, H.J. Malling, et al. 2007. Recommendations for standardization of clinical trials with allergen specific immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy 62: 317–324.
Ciprandi, G., M. De Amici, G. Murdaca, D. Fenoglio, F. Ricciardolo, G. Marseglia, et al. 2009. Serum interleukin-17 levels are related to clinical severity in allergic rhinitis. Allergy 64: 1375–1378.
Ciprandi, G., D. Fenoglio, M. De Amici, S. Quaglini, S. Negrini, and G. Filaci. 2008. Serum IL-17 levels in patients with allergic rhinitis. Journal of Allergy and Clinical Immunology 122(650–651), e652.
Liu, T., C.H. Song, A.M. Liu, C. Xie, F. Zhao, X. Chen, et al. 2011. Forkhead box P3+ T cells express interleukin-17 in nasal mucosa of patients with both allergic rhinitis and polyposis. Clinical and Experimental Immunology 163: 59–64.
Lajoie, S., I.P. Lewkowich, Y. Suzuki, J.R. Clark, A.A. Sproles, K. Dienger, et al. 2010. Complement-mediated regulation of the IL-17A axis is a central genetic determinant of the severity of experimental allergic asthma. Nature Immunology 11: 928–935.
Grailer, J.J., M. Bosmann, and P.A. Ward. 2012. Regulatory effects of C5a on IL-17A, IL-17F, and IL-23. Frontiers in Immunology 3: 387.
Andersson, M., L. Michel, J.B. Llull, and U. Pipkorn. 1994. Complement activation on the nasal mucosal surface—a feature of the immediate allergic reaction in the nose. Allergy 49: 242–245.
Hidvegi, T., B. Schmidt, L. Varga, M. Dervaderics, A. Lantos, Z. Gonczi, et al. 1995. In vitro complement activation by ragweed allergen extract in the sera of ragweed allergic and non-allergic persons. Immunology Letters 48: 65–71.
Zhang, X., and J. Kohl. 2010. A complex role for complement in allergic asthma. Expert Review of Clinical Immunology 6: 269–277.
Klos, A., A.J. Tenner, K.O. Johswich, R.R. Ager, E.S. Reis, and J. Kohl. 2009. The role of the anaphylatoxins in health and disease. Molecular Immunology 46: 2753–2766.
Mizutani, N., H. Goshima, T. Nabe, and S. Yoshino. 2012. Complement C3a-induced IL-17 plays a critical role in an IgE-mediated late-phase asthmatic response and airway hyperresponsiveness via neutrophilic inflammation in mice. Journal of Immunology 188: 5694–5705.
Kohl, J., and M. Wills-Karp. 2007. A dual role for complement in allergic asthma. Current Opinion in Pharmacology 7: 283–289.
Engelke, C., A.V. Wiese, I. Schmudde, F. Ender, H.A. Strover, T. Vollbrandt, et al. 2014. Distinct roles of the anaphylatoxins C3a and C5a in dendritic cell-mediated allergic asthma. Journal of Immunology 193: 5387–5401.
Zhang, X., I. Schmudde, Y. Laumonnier, M.K. Pandey, J.R. Clark, P. Konig, et al. 2010. A critical role for C5L2 in the pathogenesis of experimental allergic asthma. Journal of Immunology 185: 6741–6752.
Locksley, R.M. 2008. The roaring twenties. Immunity 28: 437–439.
Cosmi, L., L. Maggi, V. Santarlasci, M. Capone, E. Cardilicchia, F. Frosali, et al. 2010. Identification of a novel subset of human circulating memory CD4(+) T cells that produce both IL-17A and IL-4. Journal of Allergy and Clinical Immunology 125(222–230): e221–224.
Wang, Y.H., K.S. Voo, B. Liu, C.Y. Chen, B. Uygungil, W. Spoede, et al. 2010. A novel subset of CD4(+) T (H) 2 memory/effector cells that produce inflammatory IL-17 cytokine and promote the exacerbation of chronic allergic asthma. Journal of Experimental Medicine 207: 2479–2491.
Irvin, C., I. Zafar, J. Good, D. Rollins, C. Christianson, M.M. Gorska, et al. 2014. Increased frequency of dual-positive TH2/TH17 cells in bronchoalveolar lavage fluid characterizes a population of patients with severe asthma. Journal of Allergy and Clinical Immunology 134(1175–1186), e1177.
Kim, H.Y., H.J. Lee, Y.J. Chang, M. Pichavant, S.A. Shore, K.A. Fitzgerald, et al. 2014. Interleukin-17-producing innate lymphoid cells and the NLRP3 inflammasome facilitate obesity-associated airway hyperreactivity. Nature Medicine 20: 54–61.
Ramesh, R., L. Kozhaya, K. McKevitt, I.M. Djuretic, T.J. Carlson, M.A. Quintero, et al. 2014. Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids. Journal of Experimental Medicine 211: 89–104.
Funding
This work was funded by Developing Funds for Medicine (JW-2324).
Conflict of interest
The authors declare that they have no competing interests.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Author information
Authors and Affiliations
Corresponding author
Additional information
Hong Li and Enxiu Xu contributed equally to this work.
Rights and permissions
About this article
Cite this article
Li, H., Xu, E. & He, M. Cytokine Responses to Specific Immunotherapy in House Dust Mite-Induced Allergic Rhinitis Patients. Inflammation 38, 2216–2223 (2015). https://doi.org/10.1007/s10753-015-0204-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10753-015-0204-3